March 21st 2023
A genetic analysis indicates that multi-ancestry polygenic risk scores may be “potentially useful” in detecting risk of aggressive prostate cancer in patients of African ancestry, according to an expert from the University of Southern California.
March 14th 2023
Expert Perspectives on Emerging CDK4/6 Inhibitor Strategies in Advanced Prostate Cancer Management Settings
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
Clinical Vignettes: 40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®
Oncology Town Hall™: Primary Investigators Present Key Abstracts in Genitourinary Malignancies from Paris
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
Show Me Your Care Plan! Developing Multidisciplinary Strategies to Optimize the First-Line Care of Patients with mRCC
Medical Crossfire®: Key Questions on Sequencing, Radioligands, and Novel Emerging Approaches in CRPC
How Guidelines and Recent Clinical Trial Data Inform the Modern-Day Treatment of Advanced Prostate Cancer
Expert Illustrations & Commentaries™: The Role of B7-H3 Across Tumor Types and How It Could Impact Your Practice in the Future
Cases and Conversations™: How The Experts Make Evidence-Based Treatment Decisions in Castration-Resistant Prostate Cancer
Addressing Racial and Ethnic Disparities in Breast Cancer Care: Improving Outcomes Across the Spectrum of Diagnosis, Trial Access, and Patient Care
Ian D. Davis, MBBS, PhD, Dives Into Subgroup Data from the ENZAMET Trial of Enzalutamide in mHSPC at 2022 ASCOAugust 13th 2022
Ian D. Davis, MBBS, PhD, spoke about the subgroup analysis of the ENZAMET trial which analyzed enzalutamide in metastatic hormone-sensitive prostate cancer.
Metastatic CSPC: Is There a Continued Role for Docetaxel in the Frontline Setting?August 11th 2022
Shared insight on the frontline use of chemotherapy options for patients with metastatic CSPC in the context of AR-targeted therapies.
Case 1: Frontline Therapy in 63-Year-Old Man With High-Volume mCSPCAugust 11th 2022
After reviewing a patient scenario of metastatic castration-sensitive prostate cancer, expert panelists break down frontline treatment options in this setting.
Andrew J. Armstrong, MD, Details PSMA-PET Scan Parameters Indicating Better Survival Outcomes With 177Lu-PSMA-617 in mCRPCAugust 4th 2022
Data from a substudy of the phase 3 VISION trial presented at 2022 ASCO Annual Meeting showed that higher standard mean uptake value by PSMA-PET is strongly associated with outcomes for patients with metastatic castration-resistant prostate cancer.
Pembrolizumab and Chemotherapy Does Not Meet Primary End Points Despite Modest OS, rPFS Improvement in mCRPCAugust 4th 2022
Results from the phase 3 KEYNOTE-921 trial showed the primary end points of overall survival and radiographic progression-free survival were not met despite a trend towards improvement following treatment with pembrolizumab and docetaxel in patients with metastatic castration-resistant prostate cancer.
Ian D. Davis, MBBS, PhD, Details Rationale and Topline Survival Results of the ENZAMET Trial Examining Enzalutamide in mHSPC at 2022 ASCOAugust 1st 2022
Ian D. Davis, MBBS, PhD, spoke about updated survival results of the ENZAMET trial which analyzed enzalutamide in metastatic hormone-sensitive prostate cancer.
Comparison of Multimodal Therapies Identifies Equivalent Mortality Outcomes, Improved Distant Metastases in High-Risk Prostate CancerJuly 26th 2022
Radical proctectomy, external beam radiotherapy, and brachytherapy yielded comparable prostate cancer–specific mortality, while external beam radiotherapy with or without brachytherapy resulted in favorable distant metastases outcomes in patients with high-risk prostate cancer.
Cohort Study Identified Optimal Minimum Treatment Duration for ADT in High-Risk Prostate CancerJune 24th 2022
Patients with high-risk prostate cancer appeared to derive benefit from androgen deprivation therapy given for a minimal duration of over 18 months plus external beam radiotherapy.
Low/No PSMA Expressing mCRPC Tumors Respond Poorly to 177Lu-PSMA-617 TherapyJune 21st 2022
Treatment with 177Lu-PSMA-617 resulted in poor outcomes for patients with metastatic castration-resistant prostate cancer whose tumors had little to no prostate-specific membrane antigen expression.
Evidence Shows High Inter- and Intra-Reader Agreement With 18F-rhPSMA-7.3 PET/CT in Recurrent Prostate CancerJune 16th 2022
Data from the SPOTLIGHT trial indicate agreement among trained PET readers was highly concordant with use of 18F-rhPSMA-7.3 imaging for recurrent prostate cancer.
ATLAS Trial Confirms Radiotherapy Can Be Combined with Next-Gen Hormonal Therapy in Phase 3 Studies of HRLPC TreatmentsJune 9th 2022
The radiotherapy schedules used in the ATLAS trial reflect recent evidence and guideline changes for its usage in patients with high-risk localized or locally advanced prostate cancer.
Potential Biomarkers Identified in Post-Hoc Analysis of Apalutamide Plus ADT in mCRPCJune 7th 2022
A post-hoc analysis of the phase 3 TITAN trial revealed potential biomarkers that may predict overall survival in patients with metastatic castration-resistant prostate cancer receiving apalutamide plus androgen deprivation therapy.
177Lu-PSMA-617 Has Similar Survival, But Increased PROs Vs Cabazitaxel in mCRPCJune 5th 2022
Similar overall survival, better patient-reported outcomes, and fewer adverse effects were observed when patients were treated with 177Lu-PSMA-617 vs cabazitaxel in metastatic castration-resistant prostate cancer.
Addition of Darolutamide to ADT and Docetaxel Did not Worsen Safety in mHSPCMay 31st 2022
Adverse effects were found to be similar between patients with metastatic hormone-sensitive prostate cancer who were treated with darolutamide plus androgen deprivation therapy and docetaxel vs androgen deprivation therapy and docetaxel alone.
Darolutamide Yields Positive, Long-Lasting Outcomes in nmCRPC With or Without Prior Local TherapyMay 24th 2022
Three year follow-up findings from a post hoc analysis of the phase 3 ARAMIS trial indicated that darolutamide maintained a survival benefit regardless of prior local therapy for patients with nonmetastatic castration-resistant prostate cancer.
Promising Safety and Efficacy Observed With Niraparib/Abiraterone Acetate Combination for HRR-Altered mCRPCMay 23rd 2022
Adding niraparib to abiraterone acetate and prednisone improved efficacy and yielded tolerable safety for patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations.
Enzalutamide Plus ADT Yields Lasting Survival Benefit in Metastatic Hormone-Sensitive Prostate Cancer ± Prior TherapyMay 21st 2022
Findings from the phase 3 ARCHES trial highlighted a long-lasting survival improvement for patients with metastatic hormone-sensitive prostate cancer who were treated with enzalutamide plus androgen deprivation therapy regardless of whether they received prior local therapy.
Olaparib Reduced Pain and Yielded Better-Preserved HRQOL in Metastatic CRPCMay 19th 2022
Results from a phase 3 trial indicated that olaparib yielded better-preserved health-related quality of life and reduced pain burden vs the control for patients with homologous recombination repair gene–altered metastatic castration-resistant prostate cancer who progressed following a prior next-generation hormonal drug.